Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: Newsfilter
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to fall
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 239.710
Low
209.00
Averages
225.18
High
244.00
Current: 239.710
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Tech Stock Retreat: On Tuesday, the S&P 500 and Nasdaq fell by 0.70% and 1.5%, respectively, primarily dragged down by technology and momentum stocks, particularly semiconductor firms like Advanced Micro, Broadcom, and Micron, which faced sell-offs following Samsung's disappointing preliminary second-quarter earnings, prompting investors to seek refuge in safer sectors like healthcare and financials.
- Healthcare Sector Strength: Amidst a broader market downturn, the healthcare sector is thriving, with Johnson & Johnson's stock rising 3.6% on Tuesday and nearly 30% year-to-date, while Eli Lilly's shares gained 3% after JPMorgan raised its price target from $1,300 to $1,400, driven by strong GLP-1 sales and international demand for its weight-loss drug Mounjaro.
- Financial Sector Performance: The financial sector has been the best performer this month, with Wells Fargo's shares up 6.6% over the past month ahead of earnings next Tuesday, despite being down 5.3% year-to-date, as Jim Cramer suggests it could be a breakout quarter, emphasizing the need for strong performance after previous disappointments.
- Rapid Trade Review: In the rapid-fire trading segment of the video, stocks mentioned included Fiserv, Vertex, Walmart, and Rivian, highlighting the club's focus on a diversified portfolio while underscoring the importance of vigilance amidst market volatility.
See More
- Market Pullback: Stocks closed lower to end the holiday-shortened trading week, although the S&P 500 rebounded by about 1.5% after last week's decline, indicating short-term market volatility.
- Employment Data Impact: A soft June jobs report eased concerns about the Federal Reserve raising interest rates in the coming months, potentially providing some confidence to investors, yet the overall market remains affected by AI trade volatility.
- Portfolio Performance: This week, stocks in the portfolio such as Corning, Arm Holdings, and Intel faced pressure due to changing market sentiment, while software companies like Salesforce and Microsoft saw gains, both up nearly 5% for the week.
- Economic Data Preview: Next week will feature several important economic updates, including service sector activity reports and mortgage applications, which investors should monitor for their potential impact on the market.
See More
- Jobs Data Analysis: The June nonfarm payrolls increased by only 57,000, significantly below the Dow Jones estimate of 115,000, indicating a slowdown in economic recovery, which led to a positive market reaction with rising stock futures, suggesting investors are easing their expectations for the Fed's monetary policy.
- OpenAI Equity Proposal: OpenAI is considering offering a 5% stake to the U.S. government, with CEO Sam Altman arguing that this would allow the public to share in the benefits of AI, although this move may intensify regulatory scrutiny on its competitor, Anthropic.
- Palantir Rating Upgrade: DA Davidson upgraded Palantir from hold to buy with a price target of $175, implying nearly 40% upside, as analysts noted the company's impressive growth in data analytics, making its current valuation particularly attractive.
- Nvidia New Business Model: Nvidia is introducing a new business model for fast-growing AI startups by offering quick access to computing power in exchange for a share of future revenues, which is intriguing, but analysts believe Nvidia needs to ramp up stock buybacks to improve its stock performance relative to peers.
See More
- Market Recovery: Stocks rose on Tuesday as Wall Street looked to cap a strong first half of the year, despite lingering concerns about the Middle East and the sustainability of AI spending, indicating a gradual restoration of investor confidence.
- Stable Oil Prices: Following the U.S. and Iran's agreement, West Texas Intermediate crude held above $70 a barrel, suggesting a reduction in geopolitical risks that could positively impact the global economy.
- Healthcare Stock Rebound: Cardinal Health's stock continued to rally after rebounding from an unjustified sell-off, with CEO Jason Hollar's execution praised, indicating a renewed attractiveness for investments in the healthcare sector.
- Optimistic Outlook for Honeywell Aerospace: Honeywell Aerospace shares rose nearly 2%, with the market undervaluing its independent valuation post-separation, suggesting a potential 35% upside, reflecting growing investor confidence in the aerospace business.
See More
- Nike Stock Decline: Nike shares have fallen nearly 20% over the past three months and are down 48% from the August 2025 high, making it the worst performer in the Dow Industrials, only better than Chevron, indicating significant weakness in its market position.
- Year-to-Date Performance: Year-to-date, Nike's stock is down about 35%, and no other Dow constituent has performed worse in the past 12 months, highlighting the challenges it faces in the highly competitive sports apparel market.
- Constellation Brands Struggles: Constellation Brands, the maker of Corona and Modelo beers, has seen its stock drop nearly 8% in the last three months and is down 21% from its July 2025 high, reflecting pressure in its market segment.
- Healthcare Sector Strength: The healthcare sector has risen nearly 8% in the past month, with Moderna's stock surging 47%, indicating a strong recovery in the sector and investor confidence in its growth potential.
See More
- Market Rally: The S&P 500 and Nasdaq are on track to end a five-session losing streak on Monday, indicating a rebound in market sentiment, particularly with Amazon, Alphabet, and Meta Platforms leading the recovery, which could boost investor confidence.
- Healthcare Sector Surge: Corning and Palo Alto Networks reached all-time highs during Monday's session, reflecting a resurgence in the healthcare sector, which may attract more capital into this previously undervalued area, further driving industry growth.
- Executive Changes Impact: Goldman Sachs served as the exclusive financial advisor for Martin Marietta's $13.5 billion acquisition of Lhoist North America and provided fully committed debt financing, showcasing its strong performance in investment banking, which could enhance its market position.
- Economic Data Focus: This week will see the release of the consumer confidence survey and the JOLTS report, which are expected to influence market sentiment, especially ahead of the upcoming non-farm payroll report, prompting investors to closely monitor these economic indicators.
See More











